Project cooperation
nano-poly-pharmacology platform
Based on niosome and/or cyclodextrin. Validated in sepsis preclinical murin models. All types of administration routes
Theriopharm is developing drug delivery systems (DDSs) based on proprietary niosome & cyclodextrin based molecules.
The company has validated in preclinical studies a new approach based on nano-poly-pharmacology
We are holding several technology paltforms as:
tackling antibiotic resistance with non-antibiotic molecules
extending the scope of commercial antibiotics
new approach foor sepsis
new approach for Blood Brain Barrier (BBB) crossing
combination therapy for theranostic in any therapeutic field
prebiotic platform to alleviate symptoms in dysbiotic related gut diseases
Tech Focus
HEALTH AND BIOTECH
Project cooperation
nano-poly-pharmacology platform
Based on niosome and/or cyclodextrin. Validated in sepsis preclinical murin models. All types of administration routes
Project cooperation
Tackling antibiotic resistance using nano-poly-pharmacology
drug combination therapy using non-antibiotics molecules in a syngergistic approach